PTHS (Pelthos Therapeutics) NonCurrent Deferred Liabilities: $1.03 Mil (As of Mar. 2026)


PTHS Pelthos Therapeutics Inc PTHS
8 GF Score
Price $24.33
! 4 Warning Signs
View Full Analysis

What is Pelthos Therapeutics NonCurrent Deferred Liabilities?

Pelthos Therapeutics PTHS -5.59% 8 NonCurrent Deferred Liabilities is $1.03 Mil as of Mar. 2026. GuruFocus rates PTHS with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Pelthos Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $1.03 Mil.

Pelthos Therapeutics NonCurrent Deferred Liabilities Related Terms

Pelthos Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Pelthos Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pelthos Therapeutics NonCurrent Deferred Liabilities Chart

Pelthos Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 1.28

Pelthos Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 14.39 1.28 1.03
PTHS
8GF Score
Pelthos Therapeutics Inc PTHS
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $1.03 Mil mean?
Pelthos Therapeutics (PTHS) has a NonCurrent Deferred Liabilities of $1.03 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Pelthos Therapeutics and its competitors.
Is Pelthos Therapeutics' NonCurrent Deferred Liabilities too high?
Pelthos Therapeutics' current NonCurrent Deferred Liabilities is $1.03 Mil. Overall, Pelthos Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' NonCurrent Deferred Liabilities compare to CGTX and BDTX?
Pelthos Therapeutics' NonCurrent Deferred Liabilities of $1.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Pelthos Therapeutics and its competitors. Pelthos Therapeutics's current NonCurrent Deferred Liabilities is $1.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current NonCurrent Deferred Liabilities of $1.03 Mil. The current NonCurrent Deferred Liabilities is $1.03 Mil. Pelthos Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current NonCurrent Deferred Liabilities is $1.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pelthos Therapeutics Business Description

Address 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score

Get the complete analysis for PTHS

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.33
Price